Mark Gerard

BREAKING: A Chinese pharmaceutical company know as Jiangsu Sinopep-Allsino Biopharmaceutical (Sinopep), which operates with an internal Chinese Communist Party (CCP) committee reporting directly to Beijing, has executives tied to state-run programs flagged by the FBI for espionage concerns, and was recently hit with a $6.6 million fine for financial fraud, has FDA-cleared access to supply America's weight-loss drug ingredients. @US_FDA @DrMakaryFDA This is very alarming given the growing trend of Americans using GLP-1s for weight loss. While GLP-1s have helped millions of people lose weight, it’s concerning that a CCP affiliated company has been granted FDA access under the current Trump administration. Sinopep appears on the FDA's "Green List" under Import Alert 66-80. This designation means the FDA has evaluated the company and cleared it to export GLP-1 active pharmaceutical ingredients (APIs), like semaglutide, into the United States. American compounding pharmacies then use these ingredients to produce compounded weight-loss drugs prescribed to U.S. patients. In 2024 alone, Sinopep and other similar Chinese firms shipped enough semaglutide API to the U.S. to manufacture over 1 BILLION starter doses of GLP-1 drugs for the American market. Why is the FDA allowing CCP affiliated companies to supply pharmaceuticals to the American people? How does this Make America Healthy Again? @RobertKennedyJr